NASDAQ:HCAT - Health Catalyst Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $50.42
  • Forecasted Upside: -9.89 %
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 10 Buy Ratings
  • 0 Strong Buy Ratings
▼ -1.46 (-2.54%)

This chart shows the closing price for HCAT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Health Catalyst Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HCAT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HCAT

Analyst Price Target is $50.42
▼ -9.89% Downside Potential
This price target is based on 10 analysts offering 12 month price targets for Health Catalyst in the last 3 months. The average price target is $50.42, with a high forecast of $66.00 and a low forecast of $37.00. The average price target represents a -9.89% upside from the last price of $55.95.

This chart shows the closing price for HCAT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 10 polled investment analysts is to buy stock in Health Catalyst.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 14 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/30/2021SVB LeerinkBoost Price TargetOutperform$59.00 ➝ $62.00Medium
6/28/2021Raymond JamesReiterated RatingBuy$66.00Medium
5/7/2021The Goldman Sachs GroupBoost Price TargetBuy$54.00 ➝ $60.00High
5/7/2021Raymond JamesBoost Price TargetStrong-Buy$56.00 ➝ $63.00High
5/7/2021SVB LeerinkBoost Price TargetOutperform$53.00 ➝ $59.00High
5/7/2021Cantor FitzgeraldBoost Price TargetOverweight$52.00 ➝ $60.00High
5/7/2021Piper SandlerBoost Price TargetOutperform ➝ Overweight$54.00 ➝ $57.00High
4/29/2021JPMorgan Chase & Co.Initiated CoverageOverweightMedium
2/26/2021Piper SandlerBoost Price TargetOverweight$50.00 ➝ $54.00Low
2/26/2021SVB LeerinkBoost Price TargetOutperform$40.00 ➝ $53.00High
2/26/2021Raymond JamesBoost Price TargetIn-Line ➝ Strong-Buy$44.00 ➝ $56.00High
1/7/2021Canaccord GenuityBoost Price TargetFocus Stock ➝ Buy$43.00 ➝ $50.00High
12/15/2020Smith Barney CitigroupBoost Price Target$40.00 ➝ $49.00Medium
12/8/2020Berenberg BankInitiated CoverageBuy$44.00High
11/11/2020Cantor FitzgeraldReiterated RatingOverweightHigh
11/11/2020Canaccord GenuityBoost Price TargetBuy$40.00 ➝ $43.00Low
11/11/2020Royal Bank of CanadaBoost Price TargetOutperform$34.00 ➝ $40.00Medium
11/11/2020Raymond JamesBoost Price TargetPositive ➝ Strong-Buy$40.00 ➝ $44.00High
8/18/2020GuggenheimBoost Price Target$33.00 ➝ $37.00Low
8/12/2020Truist FinancialBoost Price Target$36.00 ➝ $43.00High
8/12/2020Stifel NicolausBoost Price TargetBuy$36.00 ➝ $37.00High
7/14/2020CitigroupInitiated CoverageBuy$40.00Medium
7/10/2020SVB LeerinkBoost Price TargetOutperform$32.00 ➝ $40.00High
6/18/2020Stifel NicolausInitiated CoverageBuy$36.00High
6/4/2020Cantor FitzgeraldReiterated RatingBuy$44.00Medium
5/15/2020GuggenheimInitiated CoverageBuy$33.00Low
5/13/2020SunTrust BanksBoost Price TargetBuy$30.00 ➝ $36.00Medium
5/13/2020Royal Bank of CanadaBoost Price TargetOutperform$30.00 ➝ $34.00High
5/13/2020Raymond JamesLower Price TargetStrong-Buy$46.00 ➝ $40.00High
5/13/2020SVB LeerinkBoost Price TargetOutperform$31.00 ➝ $32.00High
4/22/2020SunTrust BanksLower Price TargetBuy$35.00 ➝ $30.00Low
4/20/2020Royal Bank of CanadaInitiated CoverageOutperform$30.00Low
4/20/2020Cantor FitzgeraldLower Price TargetPositive ➝ Overweight$47.00 ➝ $44.00Low
4/13/2020SVB LeerinkInitiated CoverageOutperform$31.00High
4/2/2020Canaccord GenuityInitiated CoverageBuy$40.00Low
3/26/2020SunTrust BanksLower Price TargetBuy$46.00 ➝ $35.00Low
12/19/2019Raymond JamesInitiated CoverageStrong-Buy$46.00High
10/29/2019Cantor FitzgeraldInitiated CoverageOverweight$47.00High
8/19/2019SVB LeerinkInitiated CoverageOutperform$55.00Medium
8/19/2019The Goldman Sachs GroupInitiated CoverageBuy$49.00Medium
8/19/2019JPMorgan Chase & Co.Initiated CoverageOverweight$50.00High
8/19/2019Piper Jaffray CompaniesInitiated CoverageOverweight$47.00High
8/19/2019William BlairInitiated CoverageOutperformHigh
8/19/2019SunTrust BanksInitiated CoverageBuy$53.00High
8/19/2019Evercore ISIInitiated CoverageOutperform$50.00High
(Data available from 8/5/2016 forward)
Health Catalyst logo
Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations. Its solutions include a cloud-based data platform, analytics software, and professional services. The company was formerly known as HQC Holdings, Inc. and changed its name to Health Catalyst, Inc. in March 2017. The company was founded in 2008 and is headquartered in South Jordan, Utah.
Read More

Today's Range

Now: $55.95
Low: $55.88
High: $57.98

50 Day Range

MA: $56.22
Low: $52.85
High: $58.64

52 Week Range

Now: $55.95
Low: $29.30
High: $59.50


253,332 shs

Average Volume

268,147 shs

Market Capitalization

$2.49 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Health Catalyst?

The following Wall Street research analysts have issued stock ratings on Health Catalyst in the last twelve months: Berenberg Bank, Canaccord Genuity, Cantor Fitzgerald, Guggenheim, JPMorgan Chase & Co., Piper Sandler, Raymond James, Royal Bank of Canada, Smith Barney Citigroup, Stifel Nicolaus, SVB Leerink LLC, The Goldman Sachs Group, Inc., Truist Financial Co., and Zacks Investment Research.
View the latest analyst ratings for HCAT.

What is the current price target for Health Catalyst?

12 Wall Street analysts have set twelve-month price targets for Health Catalyst in the last year. Their average twelve-month price target is $50.42, suggesting a possible downside of 12.2%. Raymond James has the highest price target set, predicting HCAT will reach $66.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $37.00 for Health Catalyst in the next year.
View the latest price targets for HCAT.

What is the current consensus analyst rating for Health Catalyst?

Health Catalyst currently has 10 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HCAT will outperform the market and that investors should add to their positions of Health Catalyst.
View the latest ratings for HCAT.

What other companies compete with Health Catalyst?

How do I contact Health Catalyst's investor relations team?

Health Catalyst's physical mailing address is 3165 MILLROCK DRIVE SUITE 400, SALT LAKE CITY UT, 84121. The company's listed phone number is 801-708-6800 and its investor relations email address is [email protected] The official website for Health Catalyst is